Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | DRD3 | P35462 | 4/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | DRD5 | P21918 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | BAD | Q92934 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354471 | 1.00 | DRD2 (0.54) | DRD2DRD3CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL7450143 | 0.98 | DRD2 (0.53) | DRD2DRD3CHRM2CHRM1CHRM3 | |
| SCHEMBL2231378 | 0.96 | DRD2 (0.54) | DRD2DRD3CHRM2CHRM1CHRM3 | |
| Ammonia Solution, Strong SCHEMBL10371305 | 0.94 | DRD2 (0.53) | DRD2DRD3CHRM2CHRM1CHRM3 | |
| Isopropylamine SCHEMBL29202181 | 0.91 | DRD2 (0.51) | DRD2DRD3CHRM2CHRM1CHRM3 | |
| SCHEMBL19133719 | 0.87 | DRD2 (0.58) | DRD2DRD3CHRM2CHRM1CHRM3 | |
| Ammonia Solution, Strong SCHEMBL7667257 | 0.85 | DRD2 (0.56) | DRD2DRD3CHRM2CHRM1CHRM3 | |
| SCHEMBL31312989 | 0.83 | BCL2L1 (0.54) | BCL2L1BADSMN1; SMN2 | |
| SCHEMBL34467116 | 0.82 | DRD2 (0.50) | DRD2DRD3CHRM2CHRM1CHRM3 | |
| Ethylenediamine SCHEMBL11004709 | 0.82 | DRD2 (0.47) | DRD2DRD3CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0192492-B1 | PEPTIDES CONTAINING AN ALIPHATIC-AROMATIC KETONE SIDE CHAIN | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1992-01-02 | — | — | EP | claimed |
| US-20250368652-A1 | MICROBIOCIDAL BICYCLIC HETEROCYCLIC CARBOXAMIDE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2025-12-04 | — | — | US | disclosed |
| CN-117965476-A | Reductive amination enzyme mutant and application thereof in rotigotine molecular synthesis | 中国科学院天津工业生物技术研究所 | 2024-05-03 | — | — | CN | disclosed |
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220315961-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2022-10-06 | — | — | US | disclosed |
| WO-2022208382-A1 | NOVEL DIALKOXYNAPHTHO[2,3-C]FURAN-1(3H)-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASE OR SARS-COV-2 INFECTION DISEASE, COMPRISING SAME | 동화약품주식회사 | 2022-10-06 | — | — | WO | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| CN-106459019-B | Oxazoline compounds | 巴斯夫欧洲公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| US-4920227-A | Benzobicyclic carboxamide 5-HT3 antagonists | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4837301-A | FROM ALKALI MTEAL SULFIDES AND AROMATIC DIHALOGEN COMPOUNDS; IMPROVED CORROSION RESISTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-06 | — | — | US | disclosed |
| US-4677193-A | GONADOTROPIN-RELEASING FACTOR ANALOGS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1987-06-30 | — | — | US | disclosed |
| EP-0200942-A2 | New derivatives of an aminoketone | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1986-11-12 | — | — | EP | disclosed |
| EP-0192492-A2 | Peptides containing an aliphatic-aromatic ketone side chain | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1986-08-27 | — | — | EP | disclosed |
| US-4594195-A | 5,6,7,8-tetrahydro-napthonitrile intermediates | BEECHAM GROUP P.L.C. (GB) | 1986-06-10 | — | — | US | disclosed |
| US-4539319-A | Amidine derivatives | BEECHAM GROUP P.L.C. (GB) | 1985-09-03 | — | — | US | disclosed |
| EP-0097463-A2 | Amidine derivatives | BEECHAM GROUP PLC (GB) | 1984-01-04 | — | — | EP | disclosed |
| US-4115216-A | QUARTERNARY AMMONIUM COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-19 | — | — | US | disclosed |
| US-3984440-A | FOR NEOPLASIAS, DERMATOSES, INFLAMMATION AND ALLERGIES | HOFFMANN-LA ROCHE INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368652-A1 | MICROBIOCIDAL BICYCLIC HETEROCYCLIC CARBOXAMIDE DERIVATIVES | CASP1, ARG2, MPO | DRD2 1635/4885DRD3 1260/4885CHRM2 478/4885 |
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | DRD2 622/4885DRD3 504/4885CHRM2 162/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | DRD2 622/4885DRD3 504/4885CHRM2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.